- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05951985
High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners (SHIFT-AR)
High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners: A 2-Year Longitudinal Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Over the course of two years, this study will provide no-cost, twice weekly, group-based, HIFT exercise for people with neurologic diagnoses and their care partners. All participants will be required to have physician or advanced practice provider clearance to exercise. All participants will be evaluated by a physical therapist at no-cost prior to beginning the intervention to assess eligibility for the study. All eligible participants will complete a demographics questionnaire, questionnaires regarding physical and psychosocial health, and a battery of physical tests assessing mobility, strength, endurance, and balance. Participants' physical activity levels will also be monitored throughout the study through accelerometers.
Participants will participate in a maximum of twice weekly HIFT exercise for up to 2 years. All exercise programming will be led by licensed physical therapists with assistance from Doctor of Physical Therapy students. All exercise staff will be Cardiopulmonary resuscitation/basic life support certified and an automated external defibrillator will be available onsite. Exercise classes will utilize HIFT, which includes various exercises that are functional and to be performed at a high intensity. Exercises will include aerobic, resistance, and/or balance training and align with the 2018 Physical Activity Guidelines for Americans.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Reed Handlery, PhD
- Phone Number: 479-401-6016
- Email: reed.handlery@achehealth.edu
Study Contact Backup
- Name: Kaci Handlery, DPT
- Phone Number: 479-401-6017
- Email: kaci.handlery@achehealth.edu
Study Locations
-
-
Arkansas
-
Fort Smith, Arkansas, United States, 72916
- Recruiting
- Arkansas Colleges of Health Education
-
Contact:
- Reed Handlery, PhD
- Phone Number: 479-401-6016
- Email: reed.handlery@achehealth.edu
-
Contact:
- Kaci Handlery, DPT
- Phone Number: 479-401-6017
- Email: kaci.handlery@achehealth.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be at least 18 years of age
- Participants must be able to communicate and read in English
- Participants must have physician and/or advanced practice provider clearance to exercise
- Participants must have a neurologic diagnosis (e.g., spinal cord injury, Parkinson's, brain injury, stroke, poliomyelitis, multiple sclerosis, spina bifida, etc.) OR participants must be care partner of a person with neurologic diagnosis.
- Participants must possess at least 4/5 elbow flexion strength bilaterally
- Participants must be able to locomote independently (i.e., ambulate or propel a manual or power wheelchair independently).
- Participants must provide their own transportation to/from the research study
Exclusion Criteria:
- Participants will be excluded if they fail to meet any of the inclusion requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HIFT Exercise
In this single group design, all participants will be provided with up to two years of twice weekly supervised group exercise.
|
Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity.
Exercises will be tailored/modified to meet the needs of each participant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Attendance at 24 months
Time Frame: After 24 months of intervention
|
The percentage of intervention sessions attended by participants.
|
After 24 months of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in lower extremity functional strength at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Lower extremity strength will be measured via functional test (Five Times Sit to Stand).
This test records the amount of time taken to rise and sit to and from a chair five consecutive times.
Faster times indicate greater lower extremity strength.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
hange in Parkinson's Disease Questionnaire - 39 (PDQ-39) at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The PDQ-39 is a 39-item participant-reported questionnaire which assesses health-related quality of life across 8 domains (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, bodily discomfort).
Participants respond to each item using a 5-point Likert scale from 0 (never) to 4 (always).
Items in each domain are scored by expressing summed item scores as a percentage (ranging from 0 to 100%).
Lower scores indicate better quality of life.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in fast-paced gait speed at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Fast-paced walking speed will be measured via 10 meter walk test, which has individuals walk 10 meters with the middle 6 meters timed; two trials are performed and the average time is taken.
Faster walking speeds indicate greater mobility with walking.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in fast-paced wheelchair propulsion speed at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Fast-paced propulsion speed will be measured via wheelchair propulsion test, which has individuals propel 10 meters and are timed; two trials are performed and the average time is taken.
Faster propulsion speeds indicate greater mobility with wheelchair propulsion.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in 6 Minute Walk Test at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The 6 Minute Walk Test measures a participants ability to cover as much distance (measured in meters) as possible while walking for 6 minutes.
Participants will walk along a pre-defined pathway for 6 minutes, resting as needed.
The test is a measure of walking endurance with further distances indicating greater endurance.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in 6 Minute Propulsion Test at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The 6 Minute Propulsion Test measures a participants ability to cover as much distance (measured in meters) as possible while propelling a wheelchair for 6 minutes.
The test is a measure of aerobic endurance with further distances indicating greater endurance.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in Movement Disorder Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The MDS-UPDRS measures disability as a result of Parkinson's and allows tracking for progression of the disease.
The scale has four parts (1, mentation, behavior and mood, 2, activities of daily living, 3, motor examination, and 4, complications of therapy.
Each parkinsonian sign or symptom is ranked on a 5-point Likert scale (ranging from 0 to 4) with higher scores indicating greater impairments.
The minimum score on the entire scale is 0 and the maximum is 199.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in accelerometer-measured moderate-to-vigorous physical activity at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Physical activity levels will be measured via thigh or wrist-worn accelerometer (activPAL or ActiGraph).
These small devices will be worn on the less affected thigh or wrist (or non-dominant thigh or wrist for care partners).
Through collecting acceleration data, different intensities of physical activity will be inferred (i.e light, moderate and vigorous intensity physical activity), with moderate-to-vigorous intensity physical activity being used as the primary outcome measure.
At all time points, participants will wear the accelerometer for 7 consecutive days.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Participant Retention at 24 months
Time Frame: After 24 months of intervention
|
The number and percentage of participants who remain in the study through the final measurement point at 24 months.
|
After 24 months of intervention
|
Participant Recruitment Rates
Time Frame: Throughout the 24 months study period
|
The number of participants recruited will be reported as a percentage of total participants contacted for study participation.
|
Throughout the 24 months study period
|
Change in four square step test at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The four square step test measures stepping balance as the time taken to step clockwise and counterclockwise in a square pattern.
Faster times indicate greater balance.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
YMCA Bench Press Test at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The YMCA Bench Press Test measures muscular endurance of the upper body.
The test requires participants to complete as many repetitions of barbell bench press as they can with good form.
Greater number of repetitions indicates greater muscular endurance.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
30 second peak power test at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
The 30 second peak power test measures anaerobic power produced (in watts) over 30 seconds on a ski ergometer.
Greater wattage indicates greater anaerobic power.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in self-reported exercise confidence at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change will be reported using a visual analogue scale where participants rate their confidence from not confident at all to completely confident.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in self-reported pain at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change will be reported using a visual analogue scale where participants rate their pain from no pain to worst possible pain.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in self-reported sleep quality at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change will be reported using a visual analogue scale where participants rate their sleep quality from poor to exceptional.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in self-reported social support at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change will be reported using a visual analogue scale where participants rate their level of social support from people in the intervention and those outside the intervention.
The scale goes from poor to exceptional social support.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change in self-reported physical ability at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Change will be reported using a visual analogue scale where participants rate their level of ability from poor to exceptional on attributes of mobility, power, endurance/stamina, strength and balance.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Self-reported safety with program at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Using a visual analogue scale, participants rate their feelings of safety with the intervention at 24 months.
Scores range from not safe at all to exceptionally safe.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Self-reported satisfaction with coach supervision at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Using a visual analogue scale, participants rate their feelings of satisfaction with coach supervision during the intervention at 24 months.
Scores range from not satisfied at all to extremely satisfied.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Self-reported feelings of inclusion at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Using a visual analogue scale, participants rate their feelings of inclusion during the intervention at 24 months.
Scores range from minimally included to maximally included.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Self-reported feelings of exercise intensity at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Using a visual analogue scale, participants rate their feelings of exercise intensity during the intervention at 24 months.
Scores range from low intensity to high intensity exercise.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Self-reported feelings of exercise variety at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Using a visual analogue scale, participants rate their feelings on exercise variety during the intervention at 24 months.
Scores range from low exercise variety to high exercise variety.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Self-reported feelings of exercise applicability in real life at 24 months
Time Frame: After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Using a visual analogue scale, participants rate their feelings on applicability of exercises to real life during the intervention at 24 months.
Scores range from not applicable at all to extremely applicable.
|
After, 3, 6, 9, 12, 15, 18, 21 and 24 months of intervention
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, Josbeno DA, Christiansen CL, Berman BD, Kluger BM, Melanson EL, Jain S, Robichaud JA, Poon C, Corcos DM. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018 Feb 1;75(2):219-226. doi: 10.1001/jamaneurol.2017.3517.
- Ellis TD, Cavanaugh JT, DeAngelis T, Hendron K, Thomas CA, Saint-Hilaire M, Pencina K, Latham NK. Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study. Phys Ther. 2019 Feb 1;99(2):203-216. doi: 10.1093/ptj/pzy131.
- Feito Y, Heinrich KM, Butcher SJ, Poston WSC. High-Intensity Functional Training (HIFT): Definition and Research Implications for Improved Fitness. Sports (Basel). 2018 Aug 7;6(3):76. doi: 10.3390/sports6030076.
- Adams J, Lai B, Rimmer J, Powell D, Yarar-Fisher C, Oster RA, Fisher G. Telehealth high-intensity interval exercise and cardiometabolic health in spinal cord injury. Trials. 2022 Aug 4;23(1):633. doi: 10.1186/s13063-022-06585-2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Congenital Abnormalities
- Neuromuscular Diseases
- Central Nervous System Infections
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Enterovirus Infections
- Picornaviridae Infections
- Craniocerebral Trauma
- Trauma, Nervous System
- Spinal Cord Diseases
- Nervous System Malformations
- Myelitis
- Neural Tube Defects
- Neuroinflammatory Diseases
- Multiple Sclerosis
- Parkinson Disease
- Brain Injuries
- Wounds and Injuries
- Nervous System Diseases
- Spinal Cord Injuries
- Poliomyelitis
- Spinal Dysraphism
Other Study ID Numbers
- ACHE-2023-0114
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on HIFT
-
Gary Van GuilderWestern Colorado University; Auckland University of TechnologyCompletedMetabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | Atherogenic DyslipidemiaUnited States
-
University of JaenCompletedQuality of Life | AgingColombia
-
University of KansasRecruitingPhysical Disability | Mobility LimitationUnited States
-
University of Kansas Medical CenterCompleted